Download PDF
CC BY-NC-ND 4.0 · Indian Journal of Neurosurgery 2022; 11(02): 104-117
DOI: 10.1055/s-0042-1742333
Review Article

Utility of Administrative Databases and Big Data on Understanding Glioma Treatment—A Systematic Review

Monica-Rae Owens
1   Department of Neurosurgery, University of Utah, Utah, United States
,
Sarah Nguyen
1   Department of Neurosurgery, University of Utah, Utah, United States
,
Michael Karsy 
2   University of Utah Health Care, University of Utah Health Hospitals and Clinics, Utah, United States
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Background Gliomas are a heterogeneous group of tumors where large multicenter clinical and genetic studies have become increasingly popular in their understanding. We reviewed and analyzed the findings from large databases in gliomas, seeking to understand clinically relevant information.

Methods A systematic review was performed for gliomas studied using large administrative databases up to January 2020 (e.g., National Inpatient Sample [NIS], National Surgical Quality Improvement Program [NSQIP], and Surveillance, Epidemiology, and End Results Program [SEER], National Cancer Database [NCDB], and others).

Results Out of 390 screened studies, 122 were analyzed. Studies included a wide range of gliomas including low- and high-grade gliomas. The SEER database (n = 83) was the most used database followed by NCDB (n = 28). The most common pathologies included glioblastoma multiforme (GBM) (n = 67), with the next category including mixes of grades II to IV glioma (n = 31). Common study themes involved evaluation of descriptive epidemiological trends, prognostic factors, comparison of different pathologies, and evaluation of outcome trends over time. Persistent health care disparities in patient outcomes were frequently seen depending on race, marital status, insurance status, hospital volume, and location, which did not change over time. Most studies showed improvement in survival because of advances in surgical and adjuvant treatments.

Conclusions This study helps summarize the use of clinical administrative databases in gliomas research, informing on socioeconomic issues, surgical outcomes, and adjuvant treatments over time on a national level. Large databases allow for some study questions that would not be possible with single institution data; however, limitations remain in data curation, analysis, and reporting methods.

Keywords

administrative database - glioma - glioblastoma

Supplementary Material



Publication History

Article published online:
08 February 2022

© 2022. Neurological Surgeons' Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States From 2000 to 2014. JAMA Oncol 2018; 4 (09) 1254-1262
    CrossrefPubMedGoogle Scholar
  • 2 Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 2015; 38 (03) E4
    CrossrefPubMedGoogle Scholar
  • 3 Oravec CS, Motiwala M, Reed K. et al. Big data research in neurosurgery: a critical look at this popular new study design. Neurosurgery 2018; 82 (05) 728-746
    CrossrefPubMedGoogle Scholar
  • 4 Jhaveri J, Liu Y, Chowdhary M. et al. Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: an analysis of the National Cancer Data Base. Cancer 2018; 124 (06) 1169-1178
    CrossrefPubMedGoogle Scholar
  • 5 Alattar AA, Carroll KT, Bryant AK. et al. Prognostic importance of age, tumor location, and tumor grade in grade II astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and the Surveillance, Epidemiology, and End Results Database. World Neurosurg 2019; 121: e411-e418
    CrossrefPubMedGoogle Scholar
  • 6 Schupper AJ, Hirshman BR, Carroll KT, Ali MA, Carter BS, Chen CC. Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis. World Neurosurg 2017; 103: 741-747
    CrossrefPubMedGoogle Scholar
  • 7 Achey RL, Khanna V, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. J Neurooncol 2017; 133 (01) 17-25
    CrossrefPubMedGoogle Scholar
  • 8 Alattar AA, Brandel MG, Hirshman BR. et al. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Neurosurg 2018; 128 (04) 1076-1083
    CrossrefPubMedGoogle Scholar
  • 9 Brandel MG, Alattar AA, Hirshman BR. et al. Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis. J Neurooncol 2017; 133 (01) 173-181
    CrossrefPubMedGoogle Scholar
  • 10 Kinslow CJ, Garton ALA, Rae AI. et al. Extent of resection and survival for oligodendroglioma: a U.S. population-based study. J Neurooncol 2019; 144 (03) 591-601
    Google Scholar
  • 11 Lau CS, Mahendraraj K, Chamberlain RS. Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database. Cancer Manag Res 2017; 9: 159-166
    CrossrefPubMedGoogle Scholar
  • 12 Furst T, Hoffman H, Chin LS. All-cause and tumor-specific mortality trends in geriatric oligodendroglioma (OG) patients: A surveillance, epidemiology, and end results (SEER) analysis. J Clin Neurosci 2020; 73: 94-100
    CrossrefPubMedGoogle Scholar
  • 13 Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer 2011; 11: 325
    CrossrefPubMedGoogle Scholar
  • 14 Mezencev R. Epidemiology of gliomas in women diagnosed with breast cancer supports the protective role of estrogenic exposure. Bratisl Lek Listy 2018; 119 (08) 463-468
    PubMedGoogle Scholar
  • 15 Persaud-Sharma D, Burns J, Trangle J. et al. Demographic variation in the frequency of gliomas in Florida. Medicina (Kaunas) 2019; 55 (01) E5
    CrossrefPubMedGoogle Scholar
  • 16 Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004; 101 (10) 2293-2299
    CrossrefPubMedGoogle Scholar
  • 17 Jhaveri J, Cheng E, Tian S. et al. Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base. Front Oncol 2018; 8: 440
    CrossrefPubMedGoogle Scholar
  • 18 Li K, Lu D, Guo Y. et al. Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973-2014. Cancer Med 2018; 7 (10) 5281-5290
    CrossrefPubMedGoogle Scholar
  • 19 Plascak JJ, Fisher JL. Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data. PLoS One 2013; 8 (04) e60910
    CrossrefPubMedGoogle Scholar
  • 20 Gittleman H, Ostrom QT, Stetson LC. et al. Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. Neurooncol Pract 2019; 6 (06) 451-462
    PubMedGoogle Scholar
  • 21 Samaan MC, Akhtar-Danesh N. The impact of age and race on longevity in pediatric astrocytic tumors: A population-based study. Pediatr Blood Cancer 2015; 62 (09) 1567-1571
    CrossrefPubMedGoogle Scholar
  • 22 Zhao YY, Chen SH, Hao Z, Zhu HX, Xing ZL, Li MH. A nomogram for predicting individual prognosis of patients with low-grade glioma. World Neurosurg 2019; 130: e605-e612
    CrossrefPubMedGoogle Scholar
  • 23 Deb S, Pendharkar AV, Schoen MK, Altekruse S, Ratliff J, Desai A. The effect of socioeconomic status on gross total resection, radiation therapy and overall survival in patients with gliomas. J Neurooncol 2017; 132 (03) 447-453
    CrossrefPubMedGoogle Scholar
  • 24 Dong X, Noorbakhsh A, Hirshman BR. et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. Neurooncol Pract 2016; 3 (01) 29-38
    PubMedGoogle Scholar
  • 25 Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB, Abrey LE. Prognosis and patterns of care in elderly patients with glioma. Cancer 2009; 115 (23) 5534-5540
    CrossrefPubMedGoogle Scholar
  • 26 Long S, Li M, Ou S, Li G. The effect of marital status on glioma patient survival: analysis of 617 cases: A SEER-based study. Medicine (Baltimore) 2018; 97 (52) e13900
    CrossrefPubMedGoogle Scholar
  • 27 Wu J, Neale N, Huang Y. et al. Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base. World Neurosurg 2018; 112: e812-e822
    CrossrefPubMedGoogle Scholar
  • 28 Xie JC, Yang S, Liu XY, Zhao YX. Marital status is associated with survival of patients with astrocytoma. J Clin Neurosci 2018; 56: 79-87
    CrossrefPubMedGoogle Scholar
  • 29 Zhu P, Du XL, Blanco AI. et al. Impact of facility type and volume in low-grade glioma outcomes. J Neurosurg (e-pub ahead of print) DOI: 10.3171/2019.6.JNS19409.
    CrossrefPubMedGoogle Scholar
  • 30 Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 2006; 106 (06) 1358-1363
    CrossrefPubMedGoogle Scholar
  • 31 Claus EB, Walsh KM, Wiencke JK. et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015; 38 (01) E6
    CrossrefPubMedGoogle Scholar
  • 32 Jairam V, Kann BH, Park HS. et al. Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Res 2019; 39 (06) 2911-2918
    CrossrefPubMedGoogle Scholar
  • 33 Lehrer S. Glioma and Alzheimer's disease. J Alzheimers Dis Rep 2018; 2 (01) 213-218
    CrossrefPubMedGoogle Scholar
  • 34 Nguyen HS, Best B, Doan NB. et al. Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. Oncotarget 2018; 9 (70) 33271-33277
    CrossrefPubMedGoogle Scholar
  • 35 Smoll NR, Gautschi OP, Schatlo B, Schaller K, Weber DC. Relative survival of patients with supratentorial low-grade gliomas. Neuro-oncol 2012; 14 (08) 1062-1069
    CrossrefPubMedGoogle Scholar
  • 36 Youssef I, Lee A, Garay EL, Becker DJ, Schreiber D. Patterns of care and outcomes of postoperative radiation for low-grade gliomas in United States hospitals. J Clin Neurosci 2018; 58: 124-129
    CrossrefPubMedGoogle Scholar
  • 37 Missios S, Kalakoti P, Nanda A, Bekelis K. Craniotomy for glioma resection: a predictive model. World Neurosurg 2015; 83 (06) 957-964
    CrossrefPubMedGoogle Scholar
  • 38 Mukherjee D, Sarmiento JM, Nosova K. et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas. J Clin Neurosci 2014; 21 (05) 773-778
    CrossrefPubMedGoogle Scholar
  • 39 Padwal JA, Dong X, Hirshman BR, Hoi-Sang U, Carter BS, Chen CC. Superior efficacy of gross total resection in anaplastic astrocytoma patients relative to glioblastoma patients. World Neurosurg 2016; 90: 186-193
    CrossrefPubMedGoogle Scholar
  • 40 Shin JY, Diaz AZ. Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. J Neurooncol 2016; 129 (03) 557-565
    CrossrefPubMedGoogle Scholar
  • 41 Shin JY, Diaz AZ. Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. J Neurooncol 2016; 129 (03) 567-575
    CrossrefPubMedGoogle Scholar
  • 42 Shin JY, Yoon JK, Diaz AZ. Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. J Clin Neurosci 2017; 37: 34-39
    CrossrefPubMedGoogle Scholar
  • 43 Smoll NR, Hamilton B. Incidence and relative survival of anaplastic astrocytomas. Neuro-oncol 2014; 16 (10) 1400-1407
    CrossrefPubMedGoogle Scholar
  • 44 Zhao YY, Wan QS, Hao Z, Zhu HX, Xing ZL, Li MH. Clinical nomogram for predicting the survival of patients with cerebral anaplastic gliomas. Medicine (Baltimore) 2020; 99 (10) e19416
    CrossrefPubMedGoogle Scholar
  • 45 Tsao-Wei DD, Hu J, Groshen SG, Chamberlain MC. Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000. J Neurooncol 2012; 110 (01) 145-152
    CrossrefPubMedGoogle Scholar
  • 46 Champeaux C, Weller J. Implantation of carmustine wafers (Gliadel) for high-grade glioma treatment. A 9-year nationwide retrospective study. J Neurooncol 2020; 147 (01) 159-169
    CrossrefPubMedGoogle Scholar
  • 47 Maxwell R, Luksik AS, Garzon-Muvdi T. et al. Population-based study determining predictors of cancer-specific mortality and survival in pediatric high-grade brainstem glioma. World Neurosurg 2018; 119: e1006-e1015
    CrossrefPubMedGoogle Scholar
  • 48 Rusthoven CG, Carlson JA, Waxweiler TV. et al. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. Int J Radiat Oncol Biol Phys 2014; 90 (04) 894-902
    CrossrefPubMedGoogle Scholar
  • 49 Yang W, Xu T, Garzon-Muvdi T, Jiang C, Huang J, Chaichana KL. Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program-Based Study. World Neurosurg 2018; 111: e323-e334
    CrossrefPubMedGoogle Scholar
  • 50 Barnholtz-Sloan JS, Williams VL, Maldonado JL. et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 2008; 108 (04) 642-648
    CrossrefPubMedGoogle Scholar
  • 51 Sun Y, Xiong ZY, Yan PF, Jiang LL, Nie CS, Wang X. Characteristics and prognostic factors of age-stratified high-grade intracranial glioma patients: a population-based analysis. Bosn J Basic Med Sci 2019; 19 (04) 375-383
    PubMedGoogle Scholar
  • 52 Xie JC, Yang S, Liu XY, Zhao YX. Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status. Cancer Med 2018; 7 (08) 3722-3742
    CrossrefPubMedGoogle Scholar
  • 53 Lee I, Adimadhyam S, Nutescu EA. et al. Bevacizumab use and the risk of arterial and venous thromboembolism in patients with high-grade gliomas: a nested case-control study. Pharmacotherapy 2019; 39 (09) 921-928
    CrossrefPubMedGoogle Scholar
  • 54 Alan N, Seicean A, Seicean S, Neuhauser D, Benzel EC, Weil RJ. Preoperative steroid use and the incidence of perioperative complications in patients undergoing craniotomy for definitive resection of a malignant brain tumor. J Clin Neurosci 2015; 22 (09) 1413-1419
    CrossrefPubMedGoogle Scholar
  • 55 Aulakh S, DeDeo MR, Free J. et al. Survival trends in glioblastoma and association with treating facility volume. J Clin Neurosci 2019; 68: 271-274
    CrossrefPubMedGoogle Scholar
  • 56 Dressler EV, Liu M, Garcia CR. et al. Patterns and disparities of care in glioblastoma. Neurooncol Pract 2019; 6 (01) 37-46
    PubMedGoogle Scholar
  • 57 Glaser SM, Dohopolski MJ, Balasubramani GK, Flickinger JC, Beriwal S. Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival. J Neurooncol 2017; 134 (01) 107-118
    CrossrefPubMedGoogle Scholar
  • 58 Mak KS, Agarwal A, Qureshi MM, Truong MT. Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. Cancer Med 2017; 6 (06) 1192-1200
    CrossrefPubMedGoogle Scholar
  • 59 Malakhov N, Lee A, Garay E, Becker DJ, Schreiber D. Patterns of care and outcomes for glioblastoma in patients with poor performance status. J Clin Neurosci 2018; 52: 66-70
    CrossrefPubMedGoogle Scholar
  • 60 Lee A, Malakhov N, Sheth N, Wang A, Han P, Schreiber D. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Clin Neurol Neurosurg 2018; 170: 127-131
    CrossrefPubMedGoogle Scholar
  • 61 Lee A, Youssef I, Osborn VW, Safdieh J, Becker DJ, Schreiber D. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis. J Clin Neurosci 2018; 51: 85-90
    CrossrefPubMedGoogle Scholar
  • 62 Buszek SM, Al Feghali KA, Elhalawani H, Chevli N, Allen PK, Chung C. Optimal Timing of Radiotherapy Following Gross Total or Subtotal Resection of Glioblastoma: A Real-World Assessment using the National Cancer Database. Sci Rep 2020; 10 (01) 4926
    CrossrefPubMedGoogle Scholar
  • 63 Haque W, Thong Y, Verma V, Rostomily R, Brian Butler E, Teh BS. Patterns of management and outcomes of unifocal versus multifocal glioblastoma. J Clin Neurosci 2020; 74: 155-159
    CrossrefPubMedGoogle Scholar
  • 64 Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci 2018; 47: 103-110
    CrossrefPubMedGoogle Scholar
  • 65 Rhome R, Fisher R, Hormigo A, Parikh RR. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. J Neurooncol 2016; 128 (02) 241-250
    CrossrefPubMedGoogle Scholar
  • 66 Kole AJ, Park HS, Yeboa DN. et al. Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy-only” glioblastoma multiforme. Cancer 2016; 122 (15) 2364-2370
    CrossrefPubMedGoogle Scholar
  • 67 Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN. Prognostic implications of extent of resection in glioblastoma: analysis from a large database. World Neurosurg 2017; 103: 330-340
    CrossrefPubMedGoogle Scholar
  • 68 Wegner RE, Abel S, Horne ZD. et al. National trends in radiation dose escalation for glioblastoma. Radiat Oncol J 2019; 37 (01) 13-21
    CrossrefPubMedGoogle Scholar
  • 69 Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS. Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer 2014; 120 (02) 238-243
    CrossrefPubMedGoogle Scholar
  • 70 Al-Husseini MJ, Saad AM, El-Shewy KM. et al. Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study. Int J Neurosci 2019; 129 (05) 447-454
    CrossrefPubMedGoogle Scholar
  • 71 Barnholtz-Sloan JS, Maldonado JL, Williams VL. et al. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol 2007; 85 (02) 171-180
    CrossrefPubMedGoogle Scholar
  • 72 Bartek Jr J, Alattar AA, Dhawan S. et al. Receipt of brachytherapy is an independent predictor of survival in glioblastoma in the Surveillance, Epidemiology, and End Results database. J Neurooncol 2019; 145 (01) 75-83
    CrossrefPubMedGoogle Scholar
  • 73 Siker ML, Wang M, Porter K. et al. Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol 2011; 104 (01) 351-356
    CrossrefPubMedGoogle Scholar
  • 74 Thumma SR, Fairbanks RK, Lamoreaux WT. et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol 2012; 10: 75
    CrossrefPubMedGoogle Scholar
  • 75 Walker GV, Li J, Mahajan A. et al. Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis. Cancer 2012; 118 (18) 4538-4544
    CrossrefPubMedGoogle Scholar
  • 76 Yusuf MB, Gaskins J, Amsbaugh MJ, Woo S, Burton E. Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy. Neurooncol Pract 2019; 6 (02) 112-123
    PubMedGoogle Scholar
  • 77 Zinn PO, Colen RR, Kasper EM, Burkhardt JK. Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. Int J Oncol 2013; 42 (03) 929-934
    CrossrefPubMedGoogle Scholar
  • 78 Chang SM, Barker II FG. Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study. Cancer 2005; 104 (09) 1975-1984
    CrossrefPubMedGoogle Scholar
  • 79 Chen JH, Huang CY, Lee YC. et al. Comparative cost analysis for the surgical and endovascular treatment of ruptured intracranial aneurysms in Taiwan: a nationwide population-based cohort study. World Neurosurg 2018; 116: e485-e490
    CrossrefPubMedGoogle Scholar
  • 80 Darefsky AS, King Jr JT, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 2012; 118 (08) 2163-2172
    CrossrefPubMedGoogle Scholar
  • 81 Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol 2008; 64 (06) 628-634
    CrossrefPubMedGoogle Scholar
  • 82 Adams H, Adams HH, Jackson C, Rincon-Torroella J, Jallo GI, Quiñones-Hinojosa A. Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted population-based analysis. Childs Nerv Syst 2016; 32 (03) 493-503
    CrossrefPubMedGoogle Scholar
  • 83 Johnson DR, Ma DJ, Buckner JC, Hammack JE. Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer 2012; 118 (22) 5608-5613
    CrossrefPubMedGoogle Scholar
  • 84 Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107 (02) 359-364
    CrossrefPubMedGoogle Scholar
  • 85 Lam S, Lin Y, Zinn P, Su J, Pan IW. Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study. J Clin Neurosci 2018; 47: 285-293
    CrossrefPubMedGoogle Scholar
  • 86 Noorbakhsh A, Tang JA, Marcus LP. et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg 2014; 120 (01) 31-39
    CrossrefPubMedGoogle Scholar
  • 87 Pan IW, Ferguson SD, Lam S. Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000-2010. J Clin Neurosci 2015; 22 (10) 1575-1581
    CrossrefPubMedGoogle Scholar
  • 88 Porter AB, Lachance DH, Johnson DR. Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control 2015; 26 (02) 179-185
    CrossrefPubMedGoogle Scholar
  • 89 Shah BK, Bista A, Sharma S. Survival trends in elderly patients with glioblastoma in the United States: a population-based study. Anticancer Res 2016; 36 (09) 4883-4886
    CrossrefPubMedGoogle Scholar
  • 90 Tian M, Ma W, Chen Y. et al. Impact of gender on the survival of patients with glioblastoma. Biosci Rep 2018; 38 (06) BSR20180752
    CrossrefPubMedGoogle Scholar
  • 91 Wachtel MS, Yang S. Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. Cancer Med 2014; 3 (03) 660-666
    CrossrefPubMedGoogle Scholar
  • 92 Zhu P, Du XL, Lu G, Zhu JJ. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Oncotarget 2017; 8 (27) 44015-44031
    CrossrefPubMedGoogle Scholar
  • 93 Aneja S, Khullar D, Yu JB. The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme. J Neurooncol 2013; 112 (03) 393-401
    CrossrefPubMedGoogle Scholar
  • 94 Koshy M, Villano JL, Dolecek TA. et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012; 107 (01) 207-212
    CrossrefPubMedGoogle Scholar
  • 95 Shabihkhani M, Telesca D, Movassaghi M. et al. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. J Neurooncol 2017; 132 (02) 351-358
    CrossrefPubMedGoogle Scholar
  • 96 Shu C, Yan X, Zhang X, Wang Q, Cao S, Wang J. Tumor-induced mortality in adult primary supratentorial glioblastoma multiforme with different age subgroups. Future Oncol 2019; 15 (10) 1105-1114
    CrossrefPubMedGoogle Scholar
  • 97 Smoll NR, Schaller K, Gautschi OP. The cure fraction of glioblastoma multiforme. Neuroepidemiology 2012; 39 (01) 63-69
    CrossrefPubMedGoogle Scholar
  • 98 Arvold ND, Cefalu M, Wang Y, Zigler C, Schrag D, Dominici F. Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. J Neurooncol 2017; 131 (02) 301-311
    CrossrefPubMedGoogle Scholar
  • 99 Arvold ND, Wang Y, Zigler C, Schrag D, Dominici F. Hospitalization burden and survival among older glioblastoma patients. Neuro-oncol 2014; 16 (11) 1530-1540
    CrossrefPubMedGoogle Scholar
  • 100 Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 2003; 98 (03) 603-609
    CrossrefPubMedGoogle Scholar
  • 101 Bohn A, Braley A, Rodriguez de la Vega P, Zevallos JC, Barengo NC. The association between race and survival in glioblastoma patients in the US: a retrospective cohort study. PLoS One 2018; 13 (06) e0198581
    CrossrefPubMedGoogle Scholar
  • 102 Davies J, Reyes-Rivera I, Pattipaka T. et al. Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States. Neurooncol Pract 2018; 5 (04) 251-261
    PubMedGoogle Scholar
  • 103 Delavar A, Al Jammal OM, Maguire KR, Wali AR, Pham MH. The impact of rural residence on adult brain cancer survival in the United States. J Neurooncol 2019; 144 (03) 535-543
    CrossrefPubMedGoogle Scholar
  • 104 Forst D, Adams E, Nipp R. et al. Hospice utilization in patients with malignant gliomas. Neuro-oncol 2018; 20 (04) 538-545
    CrossrefPubMedGoogle Scholar
  • 105 Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer 2013; 119 (19) 3489-3495
    CrossrefPubMedGoogle Scholar
  • 106 Ladomersky E, Scholtens DM, Kocherginsky M. et al. The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma. Front Pharmacol 2019; 10: 200
    CrossrefPubMedGoogle Scholar
  • 107 Marcus LP, McCutcheon BA, Noorbakhsh A. et al. Incidence and predictors of 30-day readmission for patients discharged home after craniotomy for malignant supratentorial tumors in California (1995-2010). J Neurosurg 2014; 120 (05) 1201-1211
    CrossrefPubMedGoogle Scholar
  • 108 Pendharkar AV, Rezaii PG, Ho AL, Sussman ES, Li G, Desai AM. Functional mapping for glioma surgery: a propensity-matched analysis of outcomes and cost. World Neurosurg 2020; 137: e328-e335
    CrossrefPubMedGoogle Scholar
  • 109 Rahmani R, Tomlinson SB, Santangelo G. et al. Risk factors associated with early adverse outcomes following craniotomy for malignant glioma in older adults. J Geriatr Oncol 2020; 11 (04) 694-700
    CrossrefPubMedGoogle Scholar
  • 110 Rong X, Yang W, Garzon-Muvdi T. et al. Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study. Cancer 2016; 122 (20) 3157-3165
    CrossrefPubMedGoogle Scholar
  • 111 Huang J, Samson P, Perkins SM. et al. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol 2017; 131 (03) 593-601
    CrossrefPubMedGoogle Scholar
  • 112 Nguyen HS, Doan NB, Gelsomino M. et al. Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis. J Neurooncol 2019; 141 (01) 213-221
    CrossrefPubMedGoogle Scholar
  • 113 Zada G, Bond AE, Wang YP, Giannotta SL, Deapen D. Incidence trends in the anatomic location of primary malignant brain tumors in the United States: 1992-2006. World Neurosurg 2012; 77 (3-4): 518-524
    CrossrefPubMedGoogle Scholar
  • 114 Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT. IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget 2017; 8 (01) 191-202
    CrossrefPubMedGoogle Scholar
  • 115 Chen LF, Yang Y, Ma XD. et al. Optimizing the extent of resection and minimizing the morbidity in insular high-grade glioma surgery by high-field intraoperative MRI guidance. Turk Neurosurg 2017; 27 (05) 696-706
    PubMedGoogle Scholar
  • 116 Li X, Li Y, Cao Y. et al. Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. Int J Neurosci 2017; 127 (11) 1005-1011
    CrossrefPubMedGoogle Scholar
  • 117 Nuño M, Ly D, Mukherjee D, Ortega A, Black KL, Patil CG. Quality of surgical care and readmission in elderly glioblastoma patients. Neurooncol Pract 2014; 1 (02) 33-39
    PubMedGoogle Scholar
  • 118 Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study. Biosci Rep 2019; 39 (06) BSR20181968
    CrossrefPubMedGoogle Scholar
  • 119 Xu H, Chen J, Xu H, Qin Z. Geographic variations in the incidence of glioblastoma and prognostic factors predictive of overall survival in US adults from 2004-2013. Front Aging Neurosci 2017; 9: 352
    CrossrefPubMedGoogle Scholar
  • 120 Bin Abdulrahman AK, Bin Abdulrahman KA, Bukhari YR, Faqihi AM, Ruiz JG. Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study. Brain Behav 2019; 9 (10) e01402
    CrossrefPubMedGoogle Scholar
  • 121 Lai R, Hershman DL, Doan T, Neugut AI. The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro-oncol 2010; 12 (02) 190-198
    CrossrefPubMedGoogle Scholar
  • 122 Chen YR, Sole J, Ugiliweneza B. et al. National trends for reoperation in older patients with glioblastoma. World Neurosurg 2018; 113: e179-e189
    CrossrefPubMedGoogle Scholar
  • 123 Chen YR, Ugiliweneza B, Burton E, Woo SY, Boakye M, Skirboll S. The effect of postoperative infection on survival in patients with glioblastoma. J Neurosurg 2017; 127 (04) 807-811
    CrossrefPubMedGoogle Scholar
  • 124 Zhou X, Zhang S, Niu X. et al. Risk factors for early mortality among patients with glioma: a population-based study. World Neurosurg 2020; 136: e496-e503
    CrossrefPubMedGoogle Scholar
  • 125 Haque W, Verma V, Butler EB, Teh BS. Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma. J Neurooncol 2017; 133 (02) 369-375
    CrossrefPubMedGoogle Scholar
  • 126 Diaz-Aguilar D, ReFaey K, Clifton W. et al. Prognostic factors and survival in low grade gliomas of the spinal cord: A population-based analysis from 2006 to 2012. J Clin Neurosci 2019; 61: 14-21
    CrossrefPubMedGoogle Scholar
  • 127 Xia Y, Liao W, Huang S. et al. Nomograms for Predicting the Overall and Cancer-Specific Survival of Patients with High-Grade Glioma: A Surveillance, Epidemiology, and End Results Study. Turk Neurosurg 2020; 30 (01) 48-59
    PubMedGoogle Scholar